Emmanuel Macron and Marine Le Pen to face each other in runoffWorld April 24, 8:13
Danish defense minister accuses Russians of hacking into his staff’s emailsWorld April 24, 7:50
PROFILE: Emmanuel Macron poised to become France’s youngest presidentWorld April 24, 6:44
North Korea ready to carry out nuclear test at any time — expertsWorld April 24, 5:56
Swedish think tank puts Russia in world’s top three biggest defense spendersMilitary & Defense April 24, 4:35
Ukraine reconciliation meeting in Minsk postponed over OSCE car blastWorld April 24, 3:21
Macron announces his victory in first round of French presidential voteWorld April 24, 1:29
Le Pen gets 23.08%, Macron - 23.11% after 33 mln votes counted — Interior MinistryWorld April 23, 23:58
Preliminary results of French polls reveal defeat of two leading partiesWorld April 23, 22:49
BASEL, January 29. /ITAR-TASS/. Russia ranks second by the pharmaceutical market of over-the-counter medications, goes a report of the multinational pharmaceutical corporation Novartis.
According to the statements, the country became the world's second largest market and the strongest driver in this segment with its “double-digit growth” of over-the-counter drug sales.
As for the brands popular in Russia, Novartis cites anti-inflammatory drug Voltaren, nasal spray Otrivin and cold symptom-fighting powder Theraflu. Growth in sales of the two latter drugs increased due to cold winter, Novartis explains.
2013 financial statements came out on Wednesday showing Novartis’ revenue 2.2% up to 57.92 billion. Net profit declined 1% to 9.3 billion.
The company does not disclose over-the-counter sales summing the figure up with revenue from veterinary drugs. Sales in the segment grew 8.8% to 4.06 billion in 2013.
Novartis International AG set up in 1996 is Europe’s second pharmaceutical producer by market share with 120,000 employees operating in 140 countries. In Russia, Novartis has three kinds of businesses: over-the-counter medications, contact lenses and veterinary drugs.